2021 Essex County Council election

Marinus Pharmaceuticals Announces Presentations and Investor Event at American Epilepsy Society 2022 Annual Meeting

Retrieved on: 
Wednesday, November 30, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, COVID-19, American Epilepsy Society, Maxima and minima, Marinus, 2021 Essex County Council election, AES, EMA, Brain, Patient, Medication, CV, Ganaxolone, Annual general meeting, Webcast, Security (finance), Seizure, Epilepsy, Therapy, IV, GABAA, Clinical trial, CDKL5, FDA, Pharmaceutical industry

Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that ganaxolone data from three abstracts, including one late-breaking abstract, will be presented at the upcoming 2022 American Epilepsy Society (AES) Annual Meeting, which will be held December 2-6, 2022, in Nashville, TN.

Key Points: 
  • Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that ganaxolone data from three abstracts, including one late-breaking abstract, will be presented at the upcoming 2022 American Epilepsy Society (AES) Annual Meeting, which will be held December 2-6, 2022, in Nashville, TN.
  • Marinus will also host a scientific exhibit and investor breakfast event with members of its leadership team to highlight ganaxolones potential across a range of seizure disorders and discuss its commercial progress and strategy.
  • An archived version of the call will be available approximately two hours after the completion of the event on the website.
  • Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders.

Big Developments Set to be Unveiled at This Year's San Antonio Breast Cancer Symposium (SABCS)

Retrieved on: 
Wednesday, November 30, 2022
MOA, NEO, HER2, Epitope, Recurrence, Chain reaction, SD, LLY, TSX, 2021 Essex County Council election, EMBER, Breast cancer classification, DNA, Poster, Radar, Circulating tumor DNA, Therapy, Health, MBA, Patient, Data, Polymerase, Eli Lilly and Company, Progression-free survival, Neoplasm, Fulvestrant, Tumor microenvironment, Eli Lilly, Research, Norwich Pharma Services, TNBC, US, PCR, ONC, G1 Therapeutics, NeoGenomics, NYSE, Oncolytics Biotech, The Monarch School, MRD, News, Woman, Breast cancer, Survival, ER, Paclitaxel, Pharmaceutical industry, Medical imaging, Vaccine, Abemaciclib, Trilaciclib

VANCOUVER, British Colombia, Nov. 30, 2022 /PRNewswire/ -- USA News Group  -  A new study has revealed that women diagnosed with benign breast disease through screening have an almost double risk of acquiring breast cancer. The findings come ahead of this year's San Antonio Breast Cancer Symposium (SABCS), known as one of the largest breast cancer symposiums in the world. This year's SABCS is already shaping up to contain some big developments, including data and presentations from biotech companies such as Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Eli Lilly and Company (NYSE: LLY), NeoGenomics, Inc. (NASDAQ: NEO), Zymeworks Inc. (NYSE: ZYME), and G1 Therapeutics, Inc. (NASDAQ: GTHX).

Key Points: 
  • The findings come ahead of this year's San Antonio Breast Cancer Symposium (SABCS), known as one of the largest breast cancer symposiums in the world .
  • The second poster will include data from a collaboration with SOLTI-Innovative Cancer Research from the AWARE-1 window-of-opportunity study in early-stage breast cancer patients.
  • In addition, pharmacodynamic data from the preoperative EMBER-2 trial evaluating imlunestrant in ER+, HER2- early breast cancer will be provided.
  • Preclinical data with LOXO-783 in combination with standard-of-care breast cancer agents will also be presented at the meeting.

Big Developments Set to be Unveiled at This Year's San Antonio Breast Cancer Symposium (SABCS)

Retrieved on: 
Wednesday, November 30, 2022
MOA, NEO, HER2, Epitope, Recurrence, Chain reaction, SD, LLY, TSX, 2021 Essex County Council election, EMBER, Breast cancer classification, DNA, Poster, Radar, Circulating tumor DNA, Therapy, Health, MBA, Patient, Data, Polymerase, Eli Lilly and Company, Progression-free survival, Neoplasm, Fulvestrant, Tumor microenvironment, Eli Lilly, Research, Norwich Pharma Services, TNBC, US, PCR, ONC, G1 Therapeutics, NeoGenomics, NYSE, Oncolytics Biotech, The Monarch School, MRD, News, Woman, Breast cancer, Survival, ER, Paclitaxel, Pharmaceutical industry, Medical imaging, Vaccine, Abemaciclib, Trilaciclib

VANCOUVER, British Colombia , Nov. 30, 2022 /PRNewswire/ -- USA News Group  -  A new study has revealed that women diagnosed with benign breast disease through screening have an almost double risk of acquiring breast cancer. The findings come ahead of this year's San Antonio Breast Cancer Symposium (SABCS), known as one of the largest breast cancer symposiums in the world. This year's SABCS is already shaping up to contain some big developments, including data and presentations from biotech companies such as Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Eli Lilly and Company (NYSE: LLY), NeoGenomics, Inc. (NASDAQ: NEO), Zymeworks Inc. (NYSE: ZYME), and G1 Therapeutics, Inc. (NASDAQ: GTHX).

Key Points: 
  • The findings come ahead of this year's San Antonio Breast Cancer Symposium (SABCS), known as one of the largest breast cancer symposiums in the world .
  • The second poster will include data from a collaboration with SOLTI-Innovative Cancer Research from the AWARE-1 window-of-opportunity study in early-stage breast cancer patients.
  • In addition, pharmacodynamic data from the preoperative EMBER-2 trial evaluating imlunestrant in ER+, HER2- early breast cancer will be provided.
  • Preclinical data with LOXO-783 in combination with standard-of-care breast cancer agents will also be presented at the meeting.

BostonGene to Present at the 2022 San Antonio Breast Cancer Symposium

Retrieved on: 
Tuesday, November 29, 2022
Oncology, Medical Devices, Health, Other Health, Managed Care, General Health, Pathology, PARP, 2021 Essex County Council election, Economics, DNA, Patient, Neoplasm, Biomarker, Tumor microenvironment, Medicine, Standard of care, MD, Cancer, Research, HRD, Survival, Breast cancer, Medical imaging, Vaccine

BostonGene today announced that four abstracts have been accepted for poster presentations for the 2022 San Antonio Breast Cancer Symposium (SABCS), which will be held December 6 - 9, 2022, at the Henry B. Gonzalez Convention Center in San Antonio, Texas.

Key Points: 
  • BostonGene today announced that four abstracts have been accepted for poster presentations for the 2022 San Antonio Breast Cancer Symposium (SABCS), which will be held December 6 - 9, 2022, at the Henry B. Gonzalez Convention Center in San Antonio, Texas.
  • BostonGene developed and validated a new homologous recombination deficiency (HRD) scoring system for breast cancer patients.
  • Title: TRK inhibitor in a patient with metastatic triple-negative breast cancer and NTRK fusions identified via cell-free DNA analysis.
  • For more information, please visit the 2022 San Antonio Breast Cancer Symposium website .

Stoke Therapeutics to Present Data from the Company’s Dravet Syndrome Program at the American Epilepsy Society 2022 Annual Meeting

Retrieved on: 
Tuesday, November 29, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Linda, Development of the nervous system, American Epilepsy Society, Dravet syndrome, Risk, Cognition, Therapy, International League Against Epilepsy, Ann, Government budget balance, OLE, Stoke, Neurology, Cerebrospinal fluid, Associate, SUDEP, Patient, Intellectual disability, Hospital, Autonomic nervous system, Caregiver, Movement, Medicine, European Journal of Paediatric Neurology, Prognosis, ASO, Seizure, Plasma, FDA, Diagnosis, EMA, Disease, Safety, Sleep, Adolescence, Lurie Children's Hospital, 2021 Essex County Council election, DMPK, AES, MB, Language, Annual general meeting, Senior, SCN1A, Death, Quality of life, Feinberg School of Medicine, Pharmaceutical industry, Paint, Vaccine, Epilepsy, Pharmacokinetics, Pediatric nursing, BioAnalyt

The company is advancing STK-001 as potentially the first medicine to treat the underlying cause of Dravet syndrome.

Key Points: 
  • The company is advancing STK-001 as potentially the first medicine to treat the underlying cause of Dravet syndrome.
  • Compared with the general epilepsy population, people living with Dravet syndrome have a higher risk of sudden unexpected death in epilepsy, or SUDEP.
  • STK-001 is an investigational new medicine for the treatment of Dravet syndrome currently being evaluated in ongoing clinical trials.
  • Stokes first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy.

Aidoc Kicks Off RSNA Showing Why Radiologists Lead the Way in Healthcare AI

Retrieved on: 
Sunday, November 27, 2022
Effectiveness, AIO Robotics, Envision Healthcare, McCormick Place, EHR, Cochon, Organization, 2021 Essex County Council election, Vos, AI, Intracranial hemorrhage, Cedars-Sinai Medical Center, Triage, Risk, Hospital, RSNA, ICH, Health, Physician, AD, Patient, Electronic health record, Radiological Society of North America, Length of stay, Envision, Doctor Foster, Pulmonary embolism, Intelligence, Detection, Investment, FDA, Medical device, Risk management, Medical imaging, Mevo Horon, Aidoc, Radiology

CHICAGO, Nov. 27, 2022 /PRNewswire/ -- Aidoc, the leading provider of healthcare AI solutions, enters the Radiological Society of North America's (RSNA) 2022 annual meeting with a series of recent clearances, accolades and investments demonstrating the continued rapid adoption—and massive potential—of artificial intelligence.

Key Points: 
  • "From new funding rounds to expanding our solutions to cover multiple service lines, Aidoc has experienced numerous milestones since our time at RSNA last year," said Elad Walach, co-founder and CEO, Aidoc.
  • Additionally, Aidoc is now available in the Epic App Marketplace, enabling efficient integration with Epic's Electronic Health Records (EHR) platform.
  • These additions continue Aidoc's impressive momentum and leadership in healthcare AI, giving the organization the most FDA clearances in the AI imaging space.
  • Aidoc is the leading provider of artificial intelligence healthcare solutions that empower physicians to expedite patient treatment and enhance quality of care.

EQS-News: HepaRegeniX appoints Dr. Andreas Busch as Senior Advisor

Retrieved on: 
Sunday, November 27, 2022
Doctor of Philosophy, German Cancer Aid, MKK4, 2021 Essex County Council election, University, Therapy, Bayer, Sanofi, Patient, Senior advisor, Liver regeneration, Max Planck Institute for Molecular Genetics, Max, German Cancer Research Center, Transplant, Innovation, Max Planck Society, Pharmacy, Shire, Research, Publication, Hoechst, Survival, Takeda, Drug discovery, Pharmaceutical industry, Pharmacology

Tbingen (Germany), November 23, 2022 HepaRegeniX GmbH, a clinical stage company developing novel regenerative therapy approaches for the treatment of acute and chronic liver diseases, announced today the appointment of Dr. Andreas Busch as Senior Advisor.

Key Points: 
  • Tbingen (Germany), November 23, 2022 HepaRegeniX GmbH, a clinical stage company developing novel regenerative therapy approaches for the treatment of acute and chronic liver diseases, announced today the appointment of Dr. Andreas Busch as Senior Advisor.
  • We are thrilled to welcome Andreas Busch to our team.
  • Dr. Andreas Busch added: There is an enormous lack of organs for transplantation including of livers despite their unique inherent regenerative capabilities.
  • Dr. Andreas Busch has an extensive track record in facilitating innovation both in the pharmaceutical industry as well as in academic research.

Qualis Innovations Inc. recently announces its financial results along with updated form Company’s Chief Executive

Retrieved on: 
Thursday, November 17, 2022
Marketing, Skin, Radio, Biomedical Advanced Research and Development Authority, Risk, Therapy, Gallup (company), Internal medicine, Research, Drug development, Medical statistics, SGE, Anesthesiology, Patient, Television, Qualis (CAPES), Gallup, Ford Motor Company, FDA, Growth, Drug overdose, Hospital, Death, Consolation, Food and Drug Administration, Pain management, Consultant, Department of Medicine – University of Pamplona, Acquisition, 2021 Essex County Council election, Palliative care, Pharmacology, Opioid, Central nervous system, CNS, Nova, Johns Hopkins School of Medicine, General partnership, Pharmaceutical industry, Risk management, Medicine

Chadds Ford, Pennsylvania, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Qualis Innovations Inc. currently trades under symbol QLIS, recently announced its financial 10-Q report on November 14, 2022.

Key Points: 
  • Chadds Ford, Pennsylvania, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Qualis Innovations Inc. currently trades under symbol QLIS, recently announced its financial 10-Q report on November 14, 2022.
  • Dr. Joseph Pergolizzi provided the following update to the Companys progress and direction
    As acting Chief Executive Officer of Qualis Innovations, I want to thank you for your support for Qualis Innovations and for your loyalty and patience while we work to build value in your company.
  • I am an experienced C-suite executive who brings an extensive professional network and background in global healthcare to Qualis.
  • Please visit our SEC filings or Company's website for more information on the full results and management's plan.

SPR Therapeutics Debuts Occipital Nerve Stimulation Data at ASRA 2022

Retrieved on: 
Thursday, November 17, 2022
Sutter Health, Doctor of Philosophy, Low back pain, Judgement, Skin, Cervicogenic headache, Head, SPR, 2021 Essex County Council election, NP-hardness, Risk, Pain, Twilight anesthesia, Therapy, Chronic pain, Medtech, Patient, PNS, Database, Physician, Headache, Disability, Erythema, Society, SPRINT, OH, ASRA, Pain management, Occipital neuralgia, Neck, Knee, Quality of life, Shoulder, Infection, Neck pain, Safety, Dentistry

CLEVELAND, Nov. 17, 2022 (GLOBE NEWSWIRE) -- At the 21st Annual American Society of Regional Anesthesia (ASRA) Pain Medicine Meeting in Orlando, SPR Therapeutics is highlighting five new data sets demonstrating significant pain relief for a majority of patients resulting from 60-day PNS treatment using the SPRINT PNS System.

Key Points: 
  • CLEVELAND, Nov. 17, 2022 (GLOBE NEWSWIRE) -- At the 21st Annual American Society of Regional Anesthesia (ASRA) Pain Medicine Meeting in Orlando, SPR Therapeutics is highlighting five new data sets demonstrating significant pain relief for a majority of patients resulting from 60-day PNS treatment using the SPRINT PNS System.
  • The abstract titled Real-world evidence of significant pain relief following 60-day stimulation of occipital nerves for the treatment of chronic pain features data presented for the first time based on anonymized outcomes of patients who opted in to provide information and were treated for headache pain in the occipital region.
  • The occipital nerves are a common target for interventional management of conditions such as occipital neuralgia, cervicogenic headache, and other head pain indications and SPRINT is the only implantable PNS system that enables on-label stimulation of the occipital nerve for the treatment of chronic pain.
  • SPR Therapeutics is a privately held medical device company, providing patients with a non-opioid, minimally invasive pain treatment option.

Sermonix Pharmaceuticals Announces Four Abstracts Accepted for Presentation at 2022 San Antonio Breast Cancer Symposium

Retrieved on: 
Thursday, November 17, 2022
Quality, AstraZeneca, 2021 Essex County Council election, Mutation, DNA, ESR1, Circulating tumor DNA, Ligand Pharmaceuticals, Safety, MAF, Patient, Life, Drug development, Neoplasm, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., SERM, Therapy, Duke University, Quality of life, Woman, MBC, Breast cancer, ER, Pharmaceutical industry

COLUMBUS, Ohio, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative targeted therapeutics to specifically treat ESR1-mutated metastatic breast and gynecological cancers, today announced that it had four abstracts accepted as poster presentations at the 2022 San Antonio Breast Cancer Symposium (SABCS), which will be held Dec. 6-10 at the Henry B. Gonzalez Convention Center in San Antonio.

Key Points: 
  • COLUMBUS, Ohio, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative targeted therapeutics to specifically treat ESR1-mutated metastatic breast and gynecological cancers, today announced that it had four abstracts accepted as poster presentations at the 2022 San Antonio Breast Cancer Symposium (SABCS), which will be held Dec. 6-10 at the Henry B. Gonzalez Convention Center in San Antonio.
  • ELAINE 2 evaluated lasofoxifene in combination with the CDK4/6 inhibitor abemaciclib in a heavily pre-treated ESR1 mutation positive patient population.
  • Paul Plourde, M.D., vice president of oncology clinical development, has many decades of experience at AstraZeneca in the breast cancer drug development arena.
  • Sermonix non-executive chairman of the board is Anthony Wild, Ph.D., former president of both Parke-Davis Pharmaceuticals and Warner-Lamberts Pharmaceutical Division.